1. Cell Biology

Cytoplasmic protein misfolding titrates Hsp70 to activate nuclear Hsf1

  1. Anna E Masser
  2. Wenjing Kang
  3. Joydeep Roy
  4. Jayasankar M Kaimal
  5. Jany Quintana-Cordero
  6. Marc R Friedländer
  7. Claes Andréasson  Is a corresponding author
  1. Stockholm University, Sweden
https://doi.org/10.7554/eLife.47791
Share this article
Cite this article
  1. Anna E Masser
  2. Wenjing Kang
  3. Joydeep Roy
  4. Jayasankar M Kaimal
  5. Jany Quintana-Cordero
  6. Marc R Friedländer
  7. Claes Andréasson
(2019)
Cytoplasmic protein misfolding titrates Hsp70 to activate nuclear Hsf1
eLife 8:e47791.
https://doi.org/10.7554/eLife.47791
  2. Download BibTeX
  3. Download .RIS

Abstract

Hsf1 is an ancient transcription factor that responds to protein folding stress by inducing the heat-shock response (HSR) that restore perturbed proteostasis. Hsp70 chaperones negatively regulate the activity of Hsf1 via stress-responsive mechanisms that are poorly understood. Here we have reconstituted budding yeast Hsf1-Hsp70 activation complexes and find that surplus Hsp70 inhibits Hsf1 DNA-binding activity. Hsp70 binds Hsf1 via its canonical substrate binding domain and Hsp70 regulates Hsf1 DNA binding activity. During heat shock, Hsp70 is out-titrated by misfolded proteins derived from on-going translation in the cytosol. Pushing the boundaries of the regulatory system unveils a genetic hyper-stress program that is triggered by proteostasis collapse and involves an enlarged Hsf1 regulon. The findings demonstrate how an apparently simple chaperone-titration mechanism produces diversified transcriptional output in response to distinct stress loads.

Data availability

Sequencing data have been deposited in GEO under accession code GSE78136.

The following data sets were generated
The following previously published data sets were used

Article and author information

Author details

  1. Anna E Masser

    Department of Molecular Biosciences, The Wenner-Gren Institute, Stockholm University, Stockholm, Sweden
    Competing interests
    The authors declare that no competing interests exist.

  2. Wenjing Kang

    Science for Life Laboratory, Department of Molecular Biosciences, Stockholm University, Stockholm, Sweden
    Competing interests
    The authors declare that no competing interests exist.

  3. Joydeep Roy

    Department of Molecular Biosciences, The Wenner-Gren Institute, Stockholm University, Stockholm, Sweden
    Competing interests
    The authors declare that no competing interests exist.

  4. Jayasankar M Kaimal

    Department of Molecular Biosciences, The Wenner-Gren Institute, Stockholm University, Stockholm, Sweden
    Competing interests
    The authors declare that no competing interests exist.

  5. Jany Quintana-Cordero

    Department of Molecular Biosciences, The Wenner-Gren Institute, Stockholm University, Stockholm, Sweden
    Competing interests
    The authors declare that no competing interests exist.

  6. Marc R Friedländer

    Science for Life Laboratory, Department of Molecular Biosciences, Stockholm University, Stockholm, Sweden
    Competing interests
    The authors declare that no competing interests exist.

  7. Claes Andréasson

    Department of Molecular Biosciences, The Wenner-Gren Institute, Stockholm University, Stockholm, Sweden
    For correspondence
    claes.andreasson@su.se
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-8948-0685

Funding

The Swedish Cancer Society (CAN2018/711)

  • Claes Andréasson

The Swedish Cancer Society (CAN2016/361)

  • Claes Andréasson

Swedish Research Council (2015-05094)

  • Claes Andréasson

Knut och Alice Wallenbergs Stiftelse (2017)

  • Claes Andréasson

European Research Council (Starting Grant 758397)

  • Marc R Friedländer

Swedish Research Council (2015-04611)

  • Marc R Friedländer

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. Tricia R Serio, The University of Massachusetts, Amherst, United States

Version history

  1. Received: April 18, 2019
  2. Accepted: September 24, 2019
  3. Accepted Manuscript published: September 25, 2019 (version 1)
  4. Version of Record published: October 7, 2019 (version 2)

Copyright

© 2019, Masser et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 3,865
    Page views
  • 659
    Downloads
  • 43
    Citations

Article citation count generated by polling the highest count across the following sources: Scopus, Crossref, PubMed Central.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Anna E Masser
  2. Wenjing Kang
  3. Joydeep Roy
  4. Jayasankar M Kaimal
  5. Jany Quintana-Cordero
  6. Marc R Friedländer
  7. Claes Andréasson
(2019)
Cytoplasmic protein misfolding titrates Hsp70 to activate nuclear Hsf1
eLife 8:e47791.
https://doi.org/10.7554/eLife.47791

Categories and tags

Research organism

Further reading

    1. Cell Biology
    2. Genetics and Genomics

    Regulation of defective mitochondrial DNA accumulation and transmission in C. elegans by the programmed cell death and aging pathways

    Sagen Flowers, Rushali Kothari ... Joel H Rothman
    Research Article

    The heteroplasmic state of eukaryotic cells allows for cryptic accumulation of defective mitochondrial genomes (mtDNA). ‘Purifying selection’ mechanisms operate to remove such dysfunctional mtDNAs. We found that activators of programmed cell death (PCD), including the CED-3 and CSP-1 caspases, the BH3-only protein CED-13, and PCD corpse engulfment factors, are required in C. elegans to attenuate germline abundance of a 3.1-kb mtDNA deletion mutation, uaDf5, which is normally stably maintained in heteroplasmy with wildtype mtDNA. In contrast, removal of CED-4/Apaf1 or a mutation in the CED-4-interacting prodomain of CED-3, do not increase accumulation of the defective mtDNA, suggesting induction of a non-canonical germline PCD mechanism or non-apoptotic action of the CED-13/caspase axis. We also found that the abundance of germline mtDNAuaDf5 reproducibly increases with age of the mothers. This effect is transmitted to the offspring of mothers, with only partial intergenerational removal of the defective mtDNA. In mutants with elevated mtDNAuaDf5 levels, this removal is enhanced in older mothers, suggesting an age-dependent mechanism of mtDNA quality control. Indeed, we found that both steady-state and age-dependent accumulation rates of uaDf5 are markedly decreased in long-lived, and increased in short-lived, mutants. These findings reveal that regulators of both PCD and the aging program are required for germline mtDNA quality control and its intergenerational transmission.

    1. Biochemistry and Chemical Biology
    2. Cell Biology

    Genetically engineered mesenchymal stem cells as a nitric oxide reservoir for acute kidney injury therapy

    Haoyan Huang, Meng Qian ... Zongjin Li
    Research Article Updated

    Nitric oxide (NO), as a gaseous therapeutic agent, shows great potential for the treatment of many kinds of diseases. Although various NO delivery systems have emerged, the immunogenicity and long-term toxicity of artificial carriers hinder the potential clinical translation of these gas therapeutics. Mesenchymal stem cells (MSCs), with the capacities of self-renewal, differentiation, and low immunogenicity, have been used as living carriers. However, MSCs as gaseous signaling molecule (GSM) carriers have not been reported. In this study, human MSCs were genetically modified to produce mutant β-galactosidase (β-GALH363A). Furthermore, a new NO prodrug, 6-methyl-galactose-benzyl-oxy NONOate (MGP), was designed. MGP can enter cells and selectively trigger NO release from genetically engineered MSCs (eMSCs) in the presence of β-GALH363A. Moreover, our results revealed that eMSCs can release NO when MGP is systemically administered in a mouse model of acute kidney injury (AKI), which can achieve NO release in a precise spatiotemporal manner and augment the therapeutic efficiency of MSCs. This eMSC and NO prodrug system provides a unique and tunable platform for GSM delivery and holds promise for regenerative therapy by enhancing the therapeutic efficiency of stem cells.

    1. Biochemistry and Chemical Biology
    2. Cell Biology

    The FAM104 proteins VCF1/2 promote the nuclear localization of p97/VCP

    Maria Körner, Susanne R Meyer ... Alexander Buchberger
    Research Article Updated

    The ATPase p97 (also known as VCP, Cdc48) has crucial functions in a variety of important cellular processes such as protein quality control, organellar homeostasis, and DNA damage repair, and its de-regulation is linked to neuromuscular diseases and cancer. p97 is tightly controlled by numerous regulatory cofactors, but the full range and function of the p97–cofactor network is unknown. Here, we identify the hitherto uncharacterized FAM104 proteins as a conserved family of p97 interactors. The two human family members VCP nuclear cofactor family member 1 and 2 (VCF1/2) bind p97 directly via a novel, alpha-helical motif and associate with p97-UFD1-NPL4 and p97-UBXN2B complexes in cells. VCF1/2 localize to the nucleus and promote the nuclear import of p97. Loss of VCF1/2 results in reduced nuclear p97 levels, slow growth, and hypersensitivity to chemical inhibition of p97 in the absence and presence of DNA damage, suggesting that FAM104 proteins are critical regulators of nuclear p97 functions.